sudemycin E-OH

Sudemycin E-OH is a synthetic small molecule analog of the natural product FR901464 and belongs to the sudemycin family of spliceosome modulators. Developed through a collaboration between St. Jude Children's Research Hospital and Washington University in St. Louis, the sudemycin series was designed to target oncogenic aberrations in the spliceosome, particularly in cancers harboring mutations in splicing factors such as U2AF1. However, sudemycin E-OH is specifically characterized as an inactive analog within this class. It lacks the potent antitumor and splicing modulation activity seen in active analogs like sudemycin D1 or D6 and is primarily utilized as a negative control in preclinical research to validate the selective biological effects of active spliceosome-targeted agents.